Comparison
3 Methylglutaconic Aciduria Type 5 C1857776 vs 3q13 Microdeletion Syndrome C2931338
Clinical comparison between 3 Methylglutaconic Aciduria Type 5 and 3q13 Microdeletion Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type 5 C1857776
A genetic mitochondrial disorder that often causes movement problems, muscle stiffness, and developmental delay. Some forms involve the optic nerve and auditory system. Management focuses on supportive care and addressing specific symptoms.
3q13 Microdeletion Syndrome C2931338
A genetic disorder from missing material on chromosome 3q13, associated with developmental delays, intellectual disability, and various congenital features.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type 5 C1857776
0-5
3q13 Microdeletion Syndrome C2931338
Variable
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type 5 C1857776
severe
3q13 Microdeletion Syndrome C2931338
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type 5 C1857776
Chronic
3q13 Microdeletion Syndrome C2931338
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type 5 C1857776
No
3q13 Microdeletion Syndrome C2931338
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type 5 C1857776
metabolic
3q13 Microdeletion Syndrome C2931338
congenital
Same/different system
Category
3 Methylglutaconic Aciduria Type 5 C1857776
metabolic
3q13 Microdeletion Syndrome C2931338
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-5-C1857776 and 3q13-microdeletion-syndrome-C2931338 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type 5 C1857776 | 3q13 Microdeletion Syndrome C2931338 | Discriminating power |
|---|---|---|---|
| Movement and muscle findings | Movement problems and muscle stiffness are described. | Not specifically described; congenital features may vary. | Moderate |
| Development | Developmental delay may occur, often with early childhood onset. | Developmental delay and intellectual disability are associated; onset is variable. | Low |
| Sensory involvement | Some forms may involve optic nerve or hearing pathways. | Sensory involvement is not established in the supplied description. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type 5 C1857776 when
Early-onset movement disorder with developmental delay
Fits the described mitochondrial metabolic pattern better than a nonspecific congenital syndrome.
Moderate
Suspected organic acid or mitochondrial disorder
The metabolic category and ICD coding support targeted metabolic evaluation.
Moderate
Optic or auditory involvement with neurologic findings
These features are mentioned for some forms, but are not definitive alone.
Low
Choose 3q13 Microdeletion Syndrome C2931338 when
Multiple congenital features with developmental delay
A chromosomal microdeletion is more consistent with varied congenital findings.
Moderate
Intellectual disability without a clear metabolic pattern
The supplied description emphasizes intellectual disability and missing 3q13 material.
Moderate
Variable-onset congenital syndrome
Onset is listed as variable rather than specifically ages 0–5.
Low
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type 5 C1857776 | 3q13 Microdeletion Syndrome C2931338 | Interpretation |
|---|---|---|---|
| Urine organic acid analysis | May be used to look for abnormal organic acids; exact cutoffs are not supplied. | No characteristic organic-acid pattern is established here. | An abnormal result supports metabolic evaluation but is not itself a complete diagnosis. |
| Chromosomal microarray | Not expected to define this mitochondrial disorder. | May identify missing material at 3q13 when present. | A detected deletion supports the syndrome; absence does not exclude all genetic causes. |
| Targeted genetic testing | May investigate a mitochondrial or related genetic cause. | May confirm or characterize a 3q13 deletion. | Test choice should follow clinical findings and specialist judgment. |
Prognosis comparison
3 Methylglutaconic Aciduria Type 5 C1857776
- Outcome
- Described as severe and chronic, but individual outcome is not established.
- Factors
- Movement impairment, developmental delay, and possible sensory involvement may affect course.
3q13 Microdeletion Syndrome C2931338
- Outcome
- Described as moderate and chronic, with substantial individual variation.
- Factors
- Intellectual disability and congenital features may influence needs.
Time frame: Often lifelong; precise milestones or survival data are not supplied.
Confirmed diagnosis, associated complications, therapies, and support services influence outlook.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic impairment | Movement problems, stiffness, and developmental delay may be prominent. Developmental delay and intellectual disability are described. Severity and course are not fully established for an individual. |
| Sensory complications | Optic nerve or auditory involvement may occur in some forms. Not specifically established from the supplied data. Screening decisions require clinical assessment. |
| Congenital anomalies | Not a defining feature in the supplied description. Various congenital features may occur. The range and frequency are not established here. |
Patient education highlights
- HighDiagnosis versus test result
An abnormal laboratory or genetic finding needs specialist interpretation and does not by itself establish the full diagnosis.
- HighSupportive care
Management is individualized and focuses on symptoms, development, and associated medical needs.
- MediumFamily planning
Neither condition is communicable; inheritance counseling depends on confirmed genetic results.